Compounds having the formula (I), ##STR00001## and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are surprisingly advantageous as p38 kinase inhibitors, wherein R.sub.3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, NH.sub.2, or NH(CH.sub.3), preferably methyl; X is N or CH; and R.sub.1 through R.sub.6 are as described in the specification.